Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGAV | P06756 | 2/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561830 | 1.00 | RAB9A (0.47) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL2322993 | 0.85 | RAB9A (0.46) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL16340022 | 0.85 | PYGL (0.53) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL28130587 | 0.85 | RAB9A (0.46) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL8435071 | 0.85 | PYGL (0.53) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL9638522 | 0.85 | RAB9A (0.46) | RAB9ANPC1HPGDPOLBALDH1A1 | |
| SCHEMBL9844488 | 0.84 | ALDH1A1 (0.42) | RAB9ANPC1HPGDALDH1A1LMNA | |
| SCHEMBL3893774 | 0.83 | L3MBTL1 (0.60) | RAB9ANPC1HPGDPOLBITGB1 | |
| SCHEMBL3893777 | 0.83 | L3MBTL1 (0.60) | RAB9ANPC1HPGDPOLBITGB1 | |
| SCHEMBL30013408 | 0.82 | GAA (0.50) | RAB9ANPC1HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078364-B2 | Curable composition and use of same | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210087394-A1 | CURABLE COMPOSITION AND USE OF SAME | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3674375-A1 | CURABLE COMPOSITION AND USE OF SAME | Osaka Gas Chemicals Co., Ltd. (JP) | 2020-07-01 | — | — | EP | disclosed |
| EP-2809315-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | Lundbeck Na Ltd (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2134335-B1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2013116325-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130197090-A1 | POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS | CHELSEA THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130143868-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130116286-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8383681-B2 | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders | CHELSEA THERAPEUTICS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20080057228-A1 | Anti-glare film and liquid crystal display apparatus | SHARP CORPORATION | 2008-03-06 | — | — | US | disclosed |
| EP-0744955-B1 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | UNIV CALIFORNIA (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0744955-A4 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | UNIV CALIFORNIA (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5593960-A | PRODUCING CYCLOMARIN A FROM FERMENTATION OF STREPTOMYCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0744955-A1 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995022339-A1 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5444043-A | Cyclic depsipeptide non-steroidal antiinflammatory agent | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-22 | — | — | US | disclosed |
| US-5346828-A | Stereoisomeric enrichment of 2-amino-3-hydroxy-3-phenylpropionic acids using d-threonine aldolase | CELGENE CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0218440-A3 | N-METHYLPHENYLSERINE ALKYL ESTER DERIVATIVES AND USES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-01-13 | — | — | EP | disclosed |
| EP-0218440-A2 | N-Methylphenylserine alkyl ester derivatives and uses thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197090-A1 | POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS | PARK7, SNCA, COMT | RAB9A 184/4885NPC1 1163/4885HPGD 701/4885 |
| US-20130116286-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | ADRA1D, QDPR, ADRA2C | RAB9A 788/4885NPC1 2014/4885HPGD 350/4885 |
| US-20130143868-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | COMT, DRD2, TPH1 | RAB9A 881/4885NPC1 741/4885HPGD 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.